Skip to main content
Fig. 1 | Cancer Cell International

Fig. 1

From: Activating transcription factor 5 (ATF5) promotes tumorigenic capability and activates the Wnt/b-catenin pathway in bladder cancer

Fig. 1

Ectopic ATF5 expression is correlated with recurrence in bladder cancer. A ATF5 mRNA levels in the TCGA-BLCA dataset. B Overall survival of patients with low versus high ATF5 gene expression in TCGA-BLCA dataset. C Relapse-free survival of patients with low versus high ATF5 gene expression in TCGA-BLCA dataset. D Representative images of IHC staining in 102 non-relapse BLCA tissues and 38 BLCA tissues that recurred after therapy (left). Statistic analyses of the average staining index of ATF5 staining in paratumor bladder tissues and BLCA tissues (right). E Overall survival of BLCA patients with low versus high ATF5 expression. F Relapse-free survival of BLCA patients with low versus high ATF5 expression. Bars represent the mean ± SD of three independent experiments; *P < 0.05, **P < 0.01, ***P < 0.001. ATF5, activating transcription factor 5; TCGA, the cancer genome atlas; BLCA, bladder urothelial carcinoma; IHC, immunohistochemistry

Back to article page